Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danazol for Pulmonary Fibrosis with Short Telomeres
NCT04638517Phase 2Terminated
- Sponsor
- The University of Queensland
- Start
- Sep 2021
- Primary completion
- Jan 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of danazol in pulmonary fibrosis (PF) and dyskeratosis congenita (DC), sponsored by The University of Queensland. Primary endpoint: Change in absolute telomere length from baseline at 12 months. Started Sep 2021; status: terminated.
02
Drugs
danazol
03
Conditions
pulmonary fibrosis (PF)dyskeratosis congenita (DC)
Beyond the preview
Go deeper on NCT04638517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04638517.